Probiotic recolonisation therapy
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia . The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus , and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli , at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
1. A method for achieving sustained improvement of one or more autistic symptoms in an autistic subject in need thereof, which method comprises orally administering to said subject an effective amount of a pharmaceutical composition comprising a viable non-pathogenic Clostridium , a viable non-pathogenic Bacteroides , and a viable non-pathogenic Escherichia coli , wherein said method does not require the removal of a portion of said subject's existing enteric microflora via orthostatic lavage prior to said oral administration of said pharmaceutical composition.
2. The method of claim 1 , wherein said sustained improvement lasts for more than 12 months.
3. The method of claim 1 , wherein said method results in continuing improvement over the entire treatment period.
4. The method of claim 1 , wherein said method comprises an initial treatment regimen having a higher dosing frequency followed by a maintenance regimen having a lower dosing frequency.
5. The method of claim 1 , wherein said method comprises an initial treatment regimen having a higher dosage followed by a maintenance regimen having a lower dosage.
6. The method of claim 1 , wherein said subject exhibits one or more symptom improvements selected from the group consisting of reduced repetitive action, sleeping through the night, increased eye contact, and progressively increased word power.
7. The method of claim 1 , wherein said pharmaceutical composition is administered once, twice, or three times daily.
8. The method of claim 1 , wherein said pharmaceutical composition is in a capsule adapted for enteric delivery.
9. The method of claim 1 , wherein said pharmaceutical composition is in an enteric-coated capsule or an enteric-coated microcapsule.
10. The method of claim 1 , wherein said pharmaceutical composition is lyophilized.
11. The method of claim 1 , wherein said pharmaceutical composition comprises no antibiotic resistant populations.
12. The method of claim 1 , wherein said pharmaceutical composition comprises between about 10 9 and about 10 11 viable microbes.
13. The method of claim 1 , wherein said viable non-pathogenic Clostridium comprises a species selected from the group consisting of Clostridium absonum, Clostridium argentinense, Clostridium baratii, Clostridium bifermentans, Clostridium botulinum, Clostridium butyricum, Clostridium cadaveris, Clostridium camis, Clostridium celatum, Clostridium chauvoei, Clostridium clostridioforme, Clostridium cochlearium, Clostridium difficile, Clostridium fallax, Clostridium felsineum, Clostridium ghonii, Clostridium glycolicum, Clostridium haemolyticum, Clostridium hastiforme, Clostridium histolyticum, Clostridium indolis, Clostridium innocuum, Clostridium irregulare, Clostridium limosum, Clostridium malenominatum, Clostridium novyi, Clostridium oroticum, Clostridium paraputrificum, Clostridium perfringens, Clostridium piliforme, Clostridium putrefaciens, Clostridium putrificum, Clostridium ramosum, Clostridium sardiniense, Clostridium sartagoforme, Clostridium scindens, Clostridium septicum, Clostridium sordellii, Clostridium sphenoides, Clostridium spiroforme, Clostridium sporogenes, Clostridium subterminale, Clostridium symbiosum, Clostridium tertium, Clostridium tetani, Clostridium welchii , and Clostridium villosum.
14. The method of claim 1 , wherein said pharmaceutical composition comprises at least two species selected from the group consisting of Clostridium bifermentans, Clostridium innocuum, Clostridium ramosum , and Clostridium butyricum.
15. The method of claim 1 , wherein said viable non-pathogenic Bacteroides comprises a species selected from the group consisting of Bacteroides caccae, Bacteroides coagulans, Bacteroides eggerthii, Bacteroides forsythus, Bacteroides fragilis, Bacteroides gracilis, Bacteroides levil, Bacteroides macacae, Bacteroides merdae, Bacteroides ovatus, Bacteroides pneumosintes, Bacteroides putredinis, Bacteroides pyogenes, Bacteroides stercoris, Bacteroides tectum, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides ureolyticus , and Bacteroides vulgatus.
16. The method of claim 1 , wherein said viable non-pathogenic Bacteroides comprise a species selected from the group consisting of Bacteroides fragilis, Bacteroides thetaiotaomicron , and Bacteroides uniformis.
17. The method of claim 1 , wherein said effective dose comprises between about 10 5 and about 10 11 viable microbes, between about 10 7 and about 10 9 viable microbes, or between about 10 9 and about 10 11 viable microbes.
18. A method for treating autism in a subject in need thereof, which method comprises orally administering to said subject an effective amount of a pharmaceutical composition comprising a viable non-pathogenic Clostridium , a viable non-pathogenic Bacteroides , and a viable non-pathogenic E. coli , wherein said method does not require the removal of a portion of said subject's existing enteric microflora via orthostatic lavage prior to said oral administration of said pharmaceutical composition.
19. The method of claim 18 , wherein said treatment achieves sustained improvement of one or more autistic symptoms lasting for more than 12 months.